Fluphenazine decanoate-induced bradycardia: A case report

Neuropsychopharmacol Rep. 2022 Sep;42(3):368-373. doi: 10.1002/npr2.12251. Epub 2022 Apr 3.

Abstract

Sinus tachycardia and orthostatic hypotension have been so far reported among the negative cardiovascular complications of antipsychotic agents. This study aimed to report a case with bradycardia induced by fluphenazine decanoate administration. The patient was a 29-year-old man, admitted to the general teaching hospital in Sari, Iran, with a complaint of abdominal and gastric pain as well as weight loss following 7 months of fasting based on religious delusions. The patient developed bradycardia, 36 hours after fluphenazine decanoate administration. His pulse rate was also 46 beats per min (bpm). The antipsychotic medication was thus held and the patient did not take any drugs. On the 21st day after discontinuing this agent, the pulse rate reached 70 bpm. This case report notifies that much more attention should be paid to all patients before starting fluphenazine decanoate administration, and close cardiac monitoring must be done.

Keywords: antipsychotic agents; bradycardia; case report; fluphenazine decanoate.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents* / adverse effects
  • Bradycardia / chemically induced
  • Bradycardia / drug therapy
  • Delayed-Action Preparations
  • Fluphenazine / analogs & derivatives
  • Humans
  • Male
  • Schizophrenia* / drug therapy

Substances

  • Antipsychotic Agents
  • Delayed-Action Preparations
  • fluphenazine depot
  • Fluphenazine